HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam.

Abstract
Aging-, disease- and medication-related imbalance of central dopaminergic neurons causes functional impairment of cognition and neuropsychological delirium in humans. We attempted to develop a new delirium model using the direct dopamine agonist, apomorphine, and a choice reaction performance task performed by middle-aged rats. The psychological properties of the model were assessed by determining behavioral measures such as choice reaction time, % correct and % omission. Apomorphine (0.03-0.3 mg/kg s.c.) produced a dose-dependent impairment of task performance. The dose of 0.1 mg/kg prolonged choice reaction time, decreased % correct and increased % omission, indicating that rats had attentional deficits and a reduced arousal or vigilance but no motor deficits or reduced food motivation. This psychological and behavioral impairment of performance resembled that of clinically defined delirium. In this model, the cholinomimetic, aniracetam (10 mg/kg p.o.), reversed the performance impairment induced by apomorphine. Its two metabolites, 2-pyrrolidinone (10 and 30 mg/kg p.o.) and N-anisoyl-gamma-aminobutyric acid (GABA, 10 mg/kg p.o.), effectively reversed the performance impairment as the intact drug did. Another pyrrolidinone derivative, nefiracetam (10 and 30 mg/kg p.o.), tended to worsen the apomorphine effect. The cholinesterase inhibitor, tacrine (10 mg/kg p.o.), markedly worsened all of the behavioral measures. Neuroleptics, haloperidol (0.025 mg/kg s.c.), tiapride (30 mg/kg p.o.) and sulpiride (10 and 30 mg/kg p.o.), antagonized the apomorphine effect. The present results suggest that apomorphine-induced behavioral disturbances in the choice reaction performance task seems to be a useful delirium model and aniracetam may improve delirium through the action of 2-pyrrolidinone and N-anisoyl-GABA, presumably by facilitating dopamine release in the striatum by acting as an AMPA or metabotropic glutamate receptor agonist.
AuthorsK Nakamura, M Kurasawa, Y Tanaka
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 342 Issue 2-3 Pg. 127-38 (Jan 26 1998) ISSN: 0014-2999 [Print] Netherlands
PMID9548378 (Publication Type: Journal Article)
Chemical References
  • Antipsychotic Agents
  • Cholinesterase Inhibitors
  • Dopamine Agonists
  • Nootropic Agents
  • Pyrrolidinones
  • nefiracetam
  • Tacrine
  • aniracetam
  • Apomorphine
Topics
  • Animals
  • Antipsychotic Agents (pharmacology)
  • Apomorphine (pharmacology)
  • Attention (drug effects)
  • Choice Behavior (drug effects)
  • Cholinesterase Inhibitors (pharmacology)
  • Dopamine Agonists (pharmacology)
  • Male
  • Motor Activity (drug effects)
  • Nootropic Agents (pharmacology)
  • Psychomotor Performance (drug effects)
  • Pyrrolidinones (pharmacology)
  • Rats
  • Rats, Wistar
  • Tacrine (pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: